


SUPPLEMENT TO:

Population Pharmacokinetic-Pharmacodynamic Model of Nirogacestat Effects on B-Cell Maturation Antigen in Healthy Subjects


Todd Shearer, PhD,¹ Rex L. Williams Jr, PhD,¹ Mark Johnson, PhD¹
 Ewa Cendrowicz, PhD,² Cathrine Leonowens, PharmD, FCCP³
 Margaret Smith, BA,¹ Todd Baughman, MSC¹
 Caroline J. Breitbach, PhD,¹ Shinta Cheng, MD, PhD¹

¹SpringWorks Therapeutics, Stamford, CT, USA
²ICON BioAnalytical Laboratories, Assen, The Netherlands
³Nuventra Pharma Sciences, Durham, NC, USA

Scan QR code to access the poster content for Abstract 8027




Supplemental Figure 1. Plasma Cells Were Isolated From Whole Blood and Bone Marrow Aspirates for Determination of BCMA Receptor Density (MESF)




BCMA = B-cell maturation antigen; FSC-A = forward scatter area; FSC-H = forward scatter height; FSC-W = forward scatter width; MESF = molecules of equivalent soluble fluorochrome and is representative of the number of receptors detected on an individual cell; SSC-A = side scatter area

Supplemental Figure 2. Nirogacestat PK Model Diagnostic Plots



DV = dependent variable; PRED = population predictions; IPRED = individual predictions; CWRES = conditional weighted residuals

Supplemental Figure 3. Exposure-Response Model Diagnostic Plots



DV = dependent variable; PRED = population predictions; IPRED = individual predictions; CWRES = conditional weighted residuals